如果你知道去哪，全世界都会为你让路。做创新，忌惮被“惯性”慢慢吞噬——一种是先入为主的否定：别人都没成功，你也不会例外；另一种是路径依赖的复制：别人怎么做，你也只能照做。但近期ESMO年会传递出了新信号，国产创新药正用一连串临床成果打破“惯性”，率先成为一些前沿技术范式的突围者。而突围者，需要好产品，好数据，和好的执行力。执行力决定速度，也决定格局。当业界看到全球临床进展最领先的双抗ADC全部来自...
Source Link如果你知道去哪，全世界都会为你让路。做创新，忌惮被“惯性”慢慢吞噬——一种是先入为主的否定：别人都没成功，你也不会例外；另一种是路径依赖的复制：别人怎么做，你也只能照做。但近期ESMO年会传递出了新信号，国产创新药正用一连串临床成果打破“惯性”，率先成为一些前沿技术范式的突围者。而突围者，需要好产品，好数据，和好的执行力。执行力决定速度，也决定格局。当业界看到全球临床进展最领先的双抗ADC全部来自...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.